Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong
| Autor: | Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Terry C F Yip, Ronald Ching Wan Ma, Andrea On Yan Luk, Xinge Zhang, Alice Pik Shan Kong |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | BMJ Open, Vol 11, Iss 10 (2021) |
| Druh dokumentu: | article |
| ISSN: | 2021-0523 2044-6055 |
| DOI: | 10.1136/bmjopen-2021-052310 |
| Popis: | Objectives To investigate the association between baseline use of glucose-lowering drugs and serious clinical outcome among patients with type 2 diabetes.Design Territory-wide retrospective cohort of confirmed cases of COVID-19 between January 2020 and February 2021.Setting All public health facilities in Hong Kong.Participants 1220 patients with diabetes who were admitted for confirmed COVID-19.Primary and secondary outcome measures Composite clinical endpoint of intensive care unit admission, requirement of invasive mechanical ventilation and/or in-hospital death.Results In this cohort (median age 65.3 years, 54.3% men), 737 (60.4%) patients were treated with metformin, 385 (31.6%) with sulphonylureas, 199 (16.3%) with dipeptidyl peptidase-4 (DPP-4) inhibitors and 273 (22.4%) with insulin prior to admission. In multivariate Cox regression, use of metformin and DPP-4 inhibitors was associated with reduced incidence of the composite endpoint relative to non-use, with respective HRs of 0.51 (95% CI 0.34 to 0.77, p=0.001) and 0.46 (95% CI 0.29 to 0.71, p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|